An interventional study of Active HD-tDCS and Antipsychotics, mood stabilizers, etc. in Adolescent, Bipolar Depression and tDCS, sponsored by Jiangsu Province Nanjing Brain Hospital. Recruiting at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Jiangsu Province Nanjing Brain Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Bipolar Disorder with a site in China — 31 open to participants now, 31 under way, 1 of them phase 3. Bipolar Disorder · China.
Among the 78 studies in Bipolar Disorder with a site in China, this one is the 31st largest by planned enrollment of the 50 interventional ones that give a count, is one of 7 that started in 2025, is one of 30 with no phase, reaches primary completion later than 24 of the 30 other live ones, and was the 67th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →31 of the 78 studies in Bipolar Disorder with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 12–55 · Healthy volunteers
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–45
Shanghai Mental Health Center · Sites in China
Ages 18–64 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Argentina and 5 more countries
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 126 across the 50 interventional studies, 560 across the 28 observational. Of the 26 that completed or were terminated, 6 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 78 have an industry lead sponsor. The 10 most frequent:
Jiangsu Province Nanjing Brain Hospital is the lead sponsor of 22 studies on the registry; 17 are open to participants now.
Jiangsu Province Nanjing Brain Hospital has 2 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
10 of the studies in Bipolar Disorder with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140913Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | 2027-06-28 |
| NCT07021508First Affiliated Hospital of Zhejiang UniversityEfficacy and Safety Assessment of Temporal Interference Stimulation to Improve Bipolar Depression | 2026-12 |
| NCT07589647First Affiliated Hospital of Zhejiang UniversityResearch on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity | 2026-12-31 |
| NCT06831435Peking UniversityEffectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study | 2026-12-31 |
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 78 studies in Bipolar Disorder with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, sham-controlled clinical trial aims to evaluate the efficacy and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression. Participants will be randomly assigned to receive either active HD-tDCS or sham stimulation, in addition to routine clinical care. Biological data, including neuroimaging, blood biomarkers, voice and facial features, Photoplethysmography (PPG), Electroencephalography (EEG), and behavioral data, will be collected to explore potential predictors of treatment response.
This study aims to evaluate the efficacy and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex (S1) in adolescents with bipolar depression. Participants will be randomly assigned (1:1) to receive either active HD-tDCS or sham stimulation for 10 consecutive days (twice daily, 20 minutes each session), in addition to standard clinical care.
Multimodal assessments will be conducted at baseline, mid-treatment (after 10 sessions), and post-treatment, including clinical symptom scales, neurocognitive evaluations, structural and functional MRI, blood biomarkers (15ml of peripheral blood), as well as digital phenotyping data such as voice, EEG, PPG, sleep, and behavioral metrics.
The study also aims to identify objective biomarkers predictive of treatment response and to elucidate the neurobiological mechanisms associated with HD-tDCS applied to the S1 region. All procedures including MRI, tDCS, and assessments are non-invasive and free of charge for participants. The total duration of data collection and follow-up is expected to span approximately two years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive active HD-tDCS targeting the right S1. Anodal stimulation will be delivered at the C4 position according to the international 10-20 EEG system, with cathodes placed at FC4, C6, C2, and CP4. The current intensity is set at 2.0 mA for 20 minutes per session, administered twice daily for 10 days (total of 20 sessions). Participants received stable pharmacological treatment during the intervention period.
Device: Active HD-tDCS · Drug: Antipsychotics, mood stabilizers, etc.
Participants in this arm will receive sham HD-tDCS using the same electrode configuration as the active group (anode at C4; cathodes at FC4, C6, C2, and CP4), but without delivering effective current after the initial ramp-up. The sham stimulation mimics the sensation of real stimulation without physiological effects. Sessions will be delivered twice daily for 10 days (total of 20 sessions). Participants received stable pharmacological treatment during the intervention period.
Drug: Antipsychotics, mood stabilizers, etc. · Device: Sham HD-tDCS
HD-tDCS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4\*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.
During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.
Sham HD-tDCS is administered using the same electrode configuration as the active HD-tDCS condition. During each session, the device ramps up current briefly (typically 30 seconds) to mimic the initial sensation of stimulation, then remains off for the remainder of the 20-minute session. This method produces the same tactile perception as active stimulation without delivering a therapeutic dose of current.
Change from baseline in depressive symptoms assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17) at Week 2.
The HAMD-17 scale has 17 items. The total score ranges from 0-52, with higher score indicating more severe depressive symptoms. A total score of 0-7 is considered to be normal. Scores of 17 or higher indicate moderate, severe, or very severe depression.
Time frame: Baseline and after 2 weeks.
Change from baseline in depressive symptoms assessed by HAMD-17 after week 1.
The HAMD-17 scale has 17 items. The total score ranges from 0-52, with higher score indicating more severe depressive symptoms. A total score of 0-7 is considered to be normal. Scores of 17 or higher indicate moderate, severe, or very severe depression.
Time frame: Baseline and after 1 week.
Change in anxiety symptoms assessed by Hamilton Anxiety Rating Scale (HAMA) after week 1 and after week 2.
The HAMA consists of 14 items designed to assess the severity of a patient's anxiety. Each item is rated on a scale of 0 (not present) to 4 (severe), with a total score ranging from 0 to 56. Higher scores indicate greater anxiety. Change in total score from baseline will be calculated.
Time frame: Baseline, after 1week and after 2 weeks.
Change from baseline in the Clinical Global Impression-Severity scale (CGI-S) after week 1 and after week 2.
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms.
Time frame: Baseline and after 1 week and after 2 weeks.
Change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) after 1 week and after 2 week.
MADRS is a clinician-rated scale used to assess depressive symptom severity and detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is rated from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms). The total score of MADRS ranges from 0 to 60, with higher score indicating more severe depression.
Time frame: Baseline, after 1 week and after 2 weeks.
Change in brain functional connectivity measured by resting-state functional MRI
Resting-state functional magnetic resonance imaging (rs-fMRI) will be used to assess changes in the connectivity of the primary S1 and associated networks.
Time frame: Baseline, after 1 week and after 2 weeks.
Change in Cytokines (reported in pg/mL)
Peripheral blood biomarkers will be measured to evaluate inflammatory and immune responses to HD-tDCS treatment. Interferon-α (IFN-α) Interferon-γ (IFN-γ) Interleukin-1β (IL-1β) Interleukin-2 (IL-2) Interleukin-4 (IL-4) Interleukin-5 (IL-5) Interleukin-6 (IL-6) Interleukin-8 (IL-8) Interleukin-10 (IL-10) Interleukin-17 (IL-17) Tumor necrosis factor-alpha (TNF-α)
Time frame: Baseline, after 1 week, and after 2 weeks.
Change in Immune-inflammatory ratios (unitless)
Platelet-to-lymphocyte ratio (PLR) Neutrophil-to-lymphocyte ratio (NLR) Monocyte-to-HDL cholesterol ratio (MHR) These biomarkers are selected to reflect systemic inflammatory activity and immune status.
Time frame: Baseline, after 1 week, and after 2 weeks.
Adverse events and tolerability of HD-tDCS
Adverse events related to HD-tDCS will be monitored throughout the treatment period. Participants will be evaluated for scalp irritation, headache, dizziness, fatigue, or other discomforts after each session. Severity and frequency will be recorded using a standardized adverse event form.
Time frame: Baseline, after 1 week and after 2 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.
Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 26 months is below that.
Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.
Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Oct 2025, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangsu Province Nanjing Brain Hospital